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Abstract
Despite evidence that SARS-CoV-2 infection is systemic in nature, there is little known about the effects that SARS-CoV-2
infection or exposure has on many host cell types, including primitive and mature hematopoietic cells. The hematopoietic system
is responsible for giving rise to the very immune cells that defend against viral infection and is a source of hematopoietic stem
cells (HSCs) and progenitor cells (HPCs) which are used for hematopoietic cell transplantation (HCT) to treat hematologic
disorders, thus there is a strong need to understand how exposure to the virus may affect hematopoietic cell functions. We
examined the expression of ACE2, to which SARS-CoV-2 Spike (S) protein binds to facilitate viral entry, in cord blood derived
HSCs/HPCs and in peripheral blood derived immune cell subtypes. ACE2 is expressed in low numbers of immune cells, higher
numbers of HPCs, and up to 65% of rigorously defined HSCs. We also examined effects of exposing HSCs/HPCs and immune
cells to SARS-CoV-2 S protein ex vivo. HSCs and HPCs expand less effectively and have less functional colony forming
capacity when grown with S protein, while peripheral blood monocytes upregulate CD14 expression and show distinct changes
in size and granularity. That these effects are induced by recombinant S protein alone and not the infectious viral particle suggests
that simple exposure to SARS-CoV-2 may impact HSCs/HPCs and immune cells via S protein interactions with the cells,
regardless of whether they can be infected. These data have implications for immune response to SARS-CoV-2 and for HCT.
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Introduction
The devastating effects of coronavirus disease 2019 (COVID-
19) caused by severe acute respiratory coronavirus 2 (SARS-
CoV-2) infection highlights the need to understand the virus’s
effect on host tissues [1–3]. One of the alarming aspects of
COVID-19 is the systemic nature of the disease and the pau-
city of information available regarding effects of infection on
many different host cell types [4, 5]. Hematopoietic stem cells
(HSCs) and hematopoietic progenitor cells (HPCs) have not
been well studied in context of SARS-CoV-2 infection,
though the impacts on these cell types could have important
implications for immune response, hematologic complica-
tions [6], and stem cell based therapies, such as hematopoietic
cell transplantation (HCT) [7–9]. While mature immune cells
have been a current principle focus with regard to host re-
sponses, few if any studies have examined whether these im-
mune cells are themselves susceptible to infection and what
effects exposure to the virus may have directly on immune
cells.
Coronaviruses are a family of pathogens historically not
considered highly infective or deadly until the outbreak of
severe acute respiratory syndrome (SARS) caused by the
SARS coronavirus (SARS-CoV) in 2002 and the subsequent
outbreak of Middle East respiratory syndrome (MERS)
caused by the MERS coronavirus (MERS-CoV) in 2012.
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-19 as a global pandem
ic.
COVID-19 represents the third major outbreak of a disease
caused by coronavirus infection in less than two decades,
highlighting the need to better understand this family of virus-
es in order to address the current and future public health
crises. SARS, MERS, and COVID-19 manifest primarily as
respiratory syndromes, but growing evidence indicates that
many different host cell types are infected or impacted by
coronaviruses [4, 10, 11]. The coronavirus family is so named
due to their crown-like appearance, a result of the spike (S)
proteins that extend from the viral envelope and bind host cell
membrane-bound proteins to facilitate viral entry to host cells
by endocytosis [12]. The functional host receptor that binds
SARS-CoV-2 is the cell surface glycoprotein, Angiotensin
converting enzyme 2 (ACE2) [13]. In normal physiological
context, ACE2 is a regulatory protein that converts the hor-
mone Angiotensin II to Angiotensin 1–7 [14], which is a pep-
tide involved in hypertension [15]. In this coronavirus infec-
tion, SARS-CoV-2 S protein binds to host cell ACE2, facili-
tating viral entry. Within the host cell, SARS-CoV-2 then
replicates its viral machinery to propagate infection; this is
known as a productive infection. A recent study demonstrated
that SARS-CoV-2 can infect CD4+ T cells but does not ac-
tively replicate within the host T cell [16], thus SARS-CoV-2
may affect cells in different ways, including by both produc-
tive and abortive infection.
It is important to know how HSCs/HPCs and immune cells
may be affected by SARS-CoV-2 infection because disruption
to hematopoiesis or direct impacts on immune cells can lead to
dysregulated immune responses and other hematologic com-
plications. Large percentages of COVID-19 patients have pre-
sented with lymphopenia and thrombocytopenia, suggesting
there are SARS-CoV-2 induced effects on primitive and/or
mature blood cell populations [6, 17]. Further, HSCs/HPCs
derived from bone marrow, mobilized peripheral blood, and
cord blood (CB) are sources for hematopoietic cell transplan-
tation (HCT) used to treat malignant and non-malignant he-
matologic disorders [18–21]. Thus, it is important to establish
if SARS-CoV-2 exposure may impact HSCs/HPCs to be used
for HCT, as this may in turn affect the efficacy of transplan-
tation. If SARS-CoV-2 exposure may impact the efficacy of
HCT, it will be critical to put in place stringent screening
procedures for stem cell donation and banking of stem cell
sources such as CB.
While the primary disease presentation for coronaviruses is
a productive infection of the lungs [2, 22], SARS-CoV and
MERS-CoV also affect the hematopoietic system via either a
productive or abortive infection that leads to aberrant cytokine
responses and in some cases induces apoptosis of immune
cells [10, 11, 23–25]. Further, a recent study demonstrated
that a subpopulation of HSCs express the ACE2 receptor
and that exposure to SARS-CoV-2 S protein leads to upregu-
lation of inflammatory response genes in these cells [26]. It is
important to evaluate how SARS-CoV-2 exposure may affect
the efficacy of HCT and the implications that may have for
CB banking and bone marrow or mobilized peripheral blood
donation [7, 9]. Here, we confirm expression of ACE2 in
subpopulations of HSCs and examine a full panel of primitive
and lineage committed progenitor cells as well as fully mature
immune cells for ACE2 expression. The expression of ACE2
on subsets of these cells indicates potential susceptibility to
interactions with SARS-CoV-2 S protein. We also demon-
strate marked suppressive effects on HPC functional colony
forming cell capacity, reduced expansion of HSCs/HPCs, and
physiological changes induced in peripheral blood (PB) cells
when cells are grown in the presence of recombinant SARS-
CoV-2 S protein. These phenotypic changes induced by re-
combinant S protein alone suggests that exposure of HSCs/
HPCs and immune cells to SARS-CoV-2 may impact primi-
tive and mature hematopoietic cells regardless of its ability to
infect them via host cell interactions with S protein.
Materials and Methods
Umbilical Cord Blood (CB) Processing
Umbilical cord blood units were obtained from the Cleveland
Cord Blood Center (CCBC), Cleveland, OH, USA, collected
through CCBC’s Volunteer Donating Communities in
Cleveland, OH, Atlanta, GA and San Francisco, CA, and were
processed as previously described [27–29] within 48 h of col-
lection. Cord blood units were washed with PBS to remove
preservatives, layered on Ficoll-Paque Plus (GE Healthcare,
Chicago, IL, USA), spun at 1600 RPM for 30 min, and low-
density cells were collected from the intermediate layer. For
RT-qPCR, low density cells were lineage depleted using the
lineage depletion kit and then enriched for CD34+ cells using
CD34 MicroBead Kit (Milltenyi Biotec, Bergisch Gladbach,
Germany). Lineage positive cells were also collected by elut-
ing from the lineage depletion column. High density blood
cells were also collected from the pellet produced by the gra-
dient spin. For expansion assays and flow cytometry analysis,
low density cells were enriched for CD34+ cells, using two
CD34MicroBead Kit columns for increased purity (up to 95%
purity). High density granulocytes were isolated by lysing red
blood cells in RBC lysis buffer (Biolegend, San Diego, CA,
USA) for 15 min.
Peripheral Blood (PB) Processing
Whole PB was obtained from healthy donors, layered on
Ficoll-Paque Plus, spun at 1600 RPM for 30 min, and low-
density cells were collected from the intermediate layer.
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Flow Cytometry Analysis
Cells were stained according to the immunophenotypes iden-
tified in Table S1 using the antibodies listed in Table S2. Cells
were blocked with human FC receptor block, incubated with
stain for 30 min at 4 °C, washed twice, and subjected to flow
cytometry on a BD LSR II or a BD LSRFortessa flow
cytometer. ACE2+ gates were set on each individual subpop-
ulation using isotype controls. Data were analyzed using
FlowJo v10.6.2 (BD, Franklin Lakes, NJ, USA).
RT-qPCR
RNA was harvested from 5 × 105-1 × 106 cells using Qiagen
RNeasy Micro Plus Kit. cDNA was synthesized using
SuperScriptIV (ThermoFisher, Waltham, MA, USA). RT-
qPCR was run on an Applied Biosystems (Foster City, CA,
USA) QuantStudio 6 using Fast SYBR Green Master Mix
(Thermo Fisher). Primers used were: ACE2_forward- 5’
CATTGGAGCAAGTGTTGGATCTT 3′; ACE2_reverse- 5’
GAGCTAATGCATGCCATTCTCA 3″; GAPDH_forward-
5’ ACCCACTCCTCCACCTTTGAC 3′; GAPDH_reverse-
5 ’ T G T T G C T G T A G C C A A A T T C G T T 3 ′ ;
TMPRSS2_forward- 5’ TCACACCAGCCATGATCTGT
3′; TMPRSS2_reverse- 5’ TATCCCCTATCAGCCACCAG
3′.
SDS-PAGE/ Western Blotting
Protein from 5 × 105 cells was harvested by directly lysing
cells in 2x Laemmli Sample Buffer (BioRad Laboratories,
Hercules, CA, USA) +/- 5% 2-mercaptoethanol. Lysed cells
were boiled for 5 min at 95 °C and spun at maximum speed
to pellet insoluble debris. Supernatants were run on 7% or
10% SDS-PAGE Mini-Protean TGX gels (BioRad) at 200 V
for 30-45 min. Proteins were transferred to 0.22 μm nitrocel-
lulose membrane (ThermoFisher). Membranes were blocked
with 5%milk, immunoblotted with 1:1000 dilution of primary
antibody, washed, incubated with 1:2500 dilution of hrp con-
jugated secondary antibodies, washed, and developed using
SuperSignal Picoluminescent substrate (ThermoFisher) and a
BioRad ChemiDoc Touch. Primary antibodies used were goat
anti-hACE2 (R&D AF933); rabbit anti-TMPRSS2 (Abcam
ab109131, Cambridge, UK); mouse anti-GAPDH
(ThermoFisher AM4300).
Colony Forming Unit (CFU) and Expansion Assays
All colony forming unit assays were plated in 1% v/v methyl-
cellulose, with 30% v/v FBS, 2 mMGlutamine, 2 × 10−5 M 2-
Mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA), 1 U/
mL Epogen (EPO) (Amgen Inc., Thousand Oaks, CA, USA),
10 ng/mL recombinant human (rhu) Granulocyte-macrophage
colony stimulating factor (GM-CSF), 10 ng/mL rhu
Interleukin-3 (IL-3), 50 ng/mL rhu Stem cell factor (SCF)
(R&D Systems, Minneapolis, MN, USA). To test direct ef-
fects of S protein on HPC colony formation capacity, 300
CD34+ enriched cells were plated in triplicate with varying
doses (10 ng/mL, 50 ng/mL, 250 ng/mL, or 1000 ng/mL) of
recombinant SARS-CoV-2 S protein (ACRO Biosystems
SPN-C52H8, Newark, DE, USA) or PBS control. To test the
effects of S protein on HSC/HPC ex vivo expansion, expan-
sion assays were performed as previously described [18, 30,
31]. 100,000–200,000 CD34+ enriched cells were plated in
liquid culture media in the presence or absence of 1 μg/mL
recombinant S protein with growth factors for expansion:
RPMI1640 + 10% FBS + 100 ng/mL rhu Thrombopoietin
(TPO), rhuSCF, rhu Fms-like tyrosine kinase 3 ligand
(FLT3L) (R&D Systems). Cells were expanded for 7 days in
a humidified 5% O2, 5% CO2, 37 °C incubator, then 1 × 10
6
cells were stained for flow cytometry analysis and 500 cells
were plated in triplicate in methylcellulose for HPC CFU as-
say. All CFU assays were grown in a humidified 5% O2, 5%
CO2, 37 °C incubator for 12 days and were scored to distin-
guish colony forming unit- granulocyte, macrophage (CFU-
GM) and colony forming unit- granulocyte, erythroid, macro-
phage, megakaryocyte (CFU-GEMM) colonies. This combi-
nation does not pick up Burst-forming unit- erythroid (BFU-
E) colonies, as previously described [32].
Neutralizing the Effects of S Protein
We tested the ability of different agents to neutralize the ef-
fects of S protein. To test whether direct effects of S protein on
HPC colony formation capacity can be neutralized, 350
CD34+ enriched cells were plated in triplicate with 250 ng
recombinant SARS-CoV-2 S protein alone, 250 ng SARS-
CoV-2 antibody (Sino Biological 40,591-MM43, Beijing,
China) alone, 250 ng soluble rhu ACE2 (Sigma Aldrich)
alone, 250 ng Angiotensin1–7 (Sigma Aldrich) alone,
250 ng recombinant S protein pre-incubated at room temper-
ature for 30 min with 250 ng SARS-CoV-2 antibody, 250 ng
recombinant S protein pre-incubated at 37 °C for 30 min with
250 ng soluble rhu ACE2 (Sigma Aldrich), or 250 ng recom-
binant S protein with 250 ng Angiotensin1–7 (Sigma
Aldrich). To test the whether the effects of S protein on
HSC/HPC ex vivo expansion could be neutralized, 100,000
CD34+ enriched cells were plated in liquid culture media with
growth factors and with 1 μg/mL recombinant SARS-CoV-
2 S protein alone, 1 μg/mL SARS-CoV-2 antibody (Sino
Biological 40,591-MM43, Beijing, China) alone, 1 μg/mL
soluble rhu ACE2 (Sigma Aldrich) alone, 1 μg/mL
Angiotensin1–7 (SigmaAldrich) alone, 1 μg/mL recombinant
S protein pre-incubated at room temperature for 30 min with
1 μg/mL SARS-CoV-2 antibody, 1 μg/mL recombinant S
protein pre-incubated at 37 °C for 30 min with 1 μg/mL
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soluble rhu ACE2 (Sigma Aldrich), or 1 μg/mL recombinant
S protein with 1 μg/mL Angiotensin1–7 (Sigma Aldrich).
Cells were expanded for 7 days in a humidified 5% O2, 5%
CO2, 37 °C incubator, then 1 × 10
6 cells were stained for flow
cytometry analysis and 500 cells were plated in triplicate in
methylcellulose for HPC CFU assay.
Statistical Analysis
For assays consisting of only two test conditions (i.e., control
versus S protein), data were analyzed using paired t-tests in-
cluding matching for the same cord blood unit or same pe-
ripheral blood donor. Where multiple t-tests were performed
for a given experiment, multiple testing correction was per-
formed, and adjusted P-value was reported. For assays
consisting ofmore than two test conditions (i.e., control versus
S protein versus input) including dose-dependence assays,
generalized linear modeling was performed using a model that
corrects for sample variability from different cord blood units
or peripheral blood donations followed by ANOVA and
TukeyHSD post-hoc testing comparing all conditions to all
other conditions. Reported P-values are the results of the
TukeyHSD post-hoc tests. This data was analyzed in R ver-
sion 3.6.3 and the code used was as follows: lm = aov(counts
~ treatment+samplenumber); anova(lm); TukeyHSD(lm). For
all CFU assays, the average counts of technical triplicates was
used as the value for biological replicates and n was deter-
mined based off of the number of biological replicates.
Results
Hematopoietic Stem and Progenitor Cells Express Cell
Surface ACE2
We examined whether CD34+ primitive CB hematopoietic
cells express ACE2 and are thus potentially susceptible to
SARS-CoV-2. RNA was harvested from lineage depleted
(lin-) CD34+ enriched cells (enriched for HSCs/HPCs), from
lineage enriched (lin+) cells (enriched for more mature blood
cells), and from high density polymorphonuclear leukocytes
(PMN). RT-qPCR demonstrates that ACE2 mRNA is
expressed in all three of these cell populations (Fig. 1a).
Protein harvested and subjected to SDS-PAGE followed by
western blotting demonstrates that ACE2 protein is also pres-
ent in these three cell populations (Fig. 1b). Cells were stained
and analyzed by FACS to determine the cell surface expres-
sion of ACE2 on rigorously immunophenotypically defined
subpopulations of HSCs/HPCs (Fig. S1, Table S1 and S2).
ACE2 was expressed on 3.3–11.6% of CD34+ cells, includ-
ing 10.1–65.1% of rigorously purified HSCs (CD34 + CD38-
CD45RA-CD49f + CD90+); 0.4–13.8% of multipotent pro-
genitor cells (MPPs; CD34 + CD38-CD45RA-CD49f-
CD90-); and 2.7–12% of multipotent lymphoid progenitor
cells (MLPs; CD34 + CD38-CD45RA + CD10+) (Fig. 1c).
ACE2 expression was observed on the cell surface of 0.1–
14.9% of cells enriched for common myeloid progenitors/
megakaryocyte-erythroid progenitors (CMPs/MEPs;
CD34 + CD38 + CD10-CD45RA-) and 0.3–13.7% of cells
enriched for granulocyte-macrophage progenitors (GMPs;
CD34 + CD38 + CD10-CD45RA+) (Fig. 1c). This suggests
that HSCs have the highest subpopulation of ACE2 express-
ing cells, making them potentially the most susceptible hema-
topoietic cells to an ACE2 dependent mechanism of SARS-
CoV-2 infection or impact on host cells. However, the per-
centage of cell surface ACE2+ cells and level of ACE2 ex-
pression in these cells varied greatly by sample within all
subpopulations of cells, and particularly in HSCs (Fig. 1d).
HSC/HPC Colony Formation Is Inhibited by SARS-CoV-
2 S Protein
To examine the functional impact of hematopoietic cell expo-
sure to SARS-CoV-2, we incubated CB derived CD34+
enriched cells with full-length recombinant S protein. We first
examined whether S protein induced changes in viable cell
growth of CD34+ cells in the presence of stimulating growth
factors (rhuTPO/rhuSCF/rhuFLT3L). We observed signifi-
cant changes in total viable cell number with cells grown in
the absence of S protein exhibiting an average 3.8-fold in-
crease in viable cells grown in the presence of S protein
exhibiting an average 2.6-fold increase in viable cells after
4 days incubation in stimulating growth conditions (Fig. 2a).
We next examined whether S protein exposure affects the
functional HPC colony forming capacity of CD34+ cells
using either freshly harvested CD34+ cells or CD34+ cells
that we stimulated overnight with stimulating growth factors
to put the cells into cycle. We plated these cells in semi-solid
methylcellulose in the presence of serum and growth factors
and with varying doses of S protein in HPC CFU assays.
Plates were scored for granulocyte-macrophage progenitors
(CFU-GM) and multipotential progenitors (CFU-GEMM). S
protein exposure induced dose-dependent decreases in CFU-
GM and CFU-GEMM colonies in unstimulated cells at 50–
250 ng/mL with significantly decreased colony formation at
250 ng/mL and 1000 ng/mL doses compared to the control
group (0 ng/mL unstimulated cells) (Fig. 2b, c). Stimulated
cells trended toward a stronger response to S protein, with
significantly decreased CFU-GM and CFU-GEMM colonies
compared to the control group (0 ng/mL unstimulated cells) at
all evaluated doses, including the lowest dose (10 ng/mL),
indicating that cycling CD34+ cells may be more sensitive
to S protein exposure (Fig. 2b, c). To test whether the direct
effects on functional HPC colony formation induced by S
protein can be neutralized, we utilized three different methods.
First, we pre-incubated S protein with a SARS-CoV-2 Spike
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neutralizing mouse monoclonal antibody (Sino Biological
40,591-MM43). This antibody was determined in develop-
ment to inhibit the infection of ACE2 expressing human cells
by SARS-CoV-2 Spike pseudovirus. Next, we included the
peptide fragment Angiotensin1–7 (Ang1–7) with S protein
addition without pre-incubation. Ang1–7 is an important
product of ACE2 that counters inflammatory responses trig-
gered by infection [26, 33] and has been used ex vivo to
reverse the inflammatory cascade induced by S protein in
primitive stem cells. Finally, we pre-incubated S protein with
soluble rhu ACE2, which can bind to S protein [13] and pre-
vents its mediation of SARS-CoV-2 pseudovirus entry into
ACE2 expressing human cells [34, 35]. All three of these
conditions were tested separately to determine whether S
protein effects on HPC CFU were neutralized in the presence
of serum and growth factors. CFU-GM (Fig. 2d) and CFU-
GEMM (Fig. 2e) numbers were rescued by all three neutral-
izing agents, indicating the observed effects are caused direct-
ly by the S protein and reveals three ways to neutralize these
direct effects.
HSC/HPC Expansion Is Significantly Inhibited by
Exposure to SARS-CoV-2 S Protein
We evaluated effects of S protein on ex vivo expansion of
CD34+ enriched cells in the presence of stimulating growth
factors. Cells were analyzed for immunophenotype by flow
cytometry and total number of cell populations per well were
Fig. 1 Subpopulations of cord blood derived HSCs/HPCs express cell
surface ACE2. (a/b) RT-qPCR to test for ACE2 mRNA expression (a)
and SDS-PAGE followed bywestern blot with indicated antibodies to test
for ACE2 protein expression (b) in CB lineage enriched (L = Lin+) cells;
low density CB lineage depleted and CD34+ enriched cells (C = Lin-
CD34+), and CB high density polymorphonuclear cells (H=PMN).
ACE2 expression is shown relative to GAPDH expression. Matching
numbers in labels indicate samples that came from the same cord blood
unit. (c) Low density cord blood CD34+ enriched cells were stained with
fluorochrome conjugated antibodies and analyzed with flow cytometry to
define the indicated immunophenotypes and determine ACE2 expression
on these subpopulations. ACE2+ gate was defined using rabbit IgG
isotype control. Matched colors of points indicate the same cord blood
unit. ACE2 staining n = 8, IgG control n = 3; stats: t-tests comparing
FITC+ % in ACE2 staining versus IgG staining, corrected for multiple
testing. *P < 0.05 (d) Histogram shows representative ACE2 staining for
HSCs from two cord blood units with the highest and lowest number of
ACE2+ cells. Also shown is rabbit IgG isotype control
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calculated. Cells incubated with/without S protein demonstrat-
ed respective average expansions of 11.9-fold/18.3-fold in-
creases in total cellularity,13.8-fold/26.4-fold increases in
CD34+ cells (Fig. 3a), 1.9-fold/4.3-fold increases in
CD34 + CD38- cells enriched for HSCs and more primitive
progenitors, and 73.7-fold/166.5-fold increases in CD34 +
CD38+ cells enriched for mature progenitors (Fig. 3b). We
observed respective expansions of 18.4-fold/29.3-fold change
in CMP/MEP enriched cells, 73.7-fold/166.5-fold increases in
GMP enriched cells (Fig. 3c), 4.1-fold/6.2-fold increases in
HSCs and 2.8-fold/4.0-fold change in MPP (Fig. 3d).
Incubation with S protein induced an average 0.86-fold de-
crease in numbers of MLP, while MLP in the absence of S
protein exhibited a modest 1.7-fold expansion (Fig. 3d). Thus,
Fig. 2 Cord blood HSCs/HPCs exhibit reduced colony forming capacity
in the presence of SARS-CoV-2 S protein. (a) CD34+ enriched cells were
plated at 100,000 cells/mL in media with stimulating growth factors
(rhuTPO/rhuSCF/rhuFLT3L) and with 1 μg/mL recombinant S protein
or PBS control and grown for 4 days in 5% O2 and 5% CO2 at 37 °C.
Viable cells were counted using a hemocytometer and Trypan Blue via-
bility stain. n = 5, stats: paired t-test, different symbols indicate the same
cord blood unit in different treatment conditions. (b-c) CD34+ enriched
cells were either taken for direct plating (unstimulated) or were grown for
24 h with stimulating growth factors (stimulated). 300 CD34+ enriched
cells were plated in triplicate with the indicated doses of recombinant S
protein or PBS control in 1% v/v methylcellulose with growth factors and
serum and grown for 12 days in 5% O2 and 5% CO2 at 37 °C. CFU/
1x106cells were calculated. Stats: general linearized modeling including
stimulated and unstimulated cells at varying doses in the same model
followed by ANOVA with TukeyHSD post hoc tests. Significance codes
indicate comparison of sample to 0 ng/mL (PBS) control in unstimulated
cells. (d-e) 350 freshly harvested CD34+ cells were plated in triplicate in
1% v/v methylcellulose with serum and growth factors and with PBS
control, 250 ng/mL recombinant S protein alone, 250 ng/mL S protein
pre-incubated with 250 ng/mL SARS-CoV-2 neutralizing antibody
(Antibody), or 250 ng/mL S protein with 250 ng/mL Angiotensin1–7
(Ang1–7) and grown for 12 days in 5% O2 and 5% CO2 at 37 °C. Total
CFU/1x106cells were calculated. Stats: general linearized modeling
followed by ANOVA with TukeyHSD post hoc tests, matched symbols
indicate the same cord blood unit in different treatment conditions.
Shown are significance codes comparing all treatment levels to PBS
control. *P < 0.05, ***P < 0.0005
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expansion of HSCs, MPPs, CMPs/MEPs, and GMPs were all
reduced in the presence of S protein. While MLPs did not
show significant expansion in any condition, there were sig-
nificantly more total MLP grown without S protein compared
to with S protein. To determine effects on expansion of func-
tional HPC, cells were expanded for 7 days in the presence of
stimulating growth factors, and in the presence or absence of S
protein, washed to remove residual unbound S protein, and
plated in HPC CFU assays in methylcellulose containing FBS
and stimulating growth factors. Cells that were expanded in
the absence of S protein exhibited significant expansion of
CFU-GM/ CFU-GEMM (13.3-fold/4-fold average expan-
sion), while cells grown in the presence of S protein did not
exhibit significant expansion in total CFU-GM/CFU-GEMM
(4.5-fold/1.8-fold average expansion) (Fig. 3e). This indicates
that ex vivo exposure to SARS-CoV-2 S protein affects the
Fig. 3 Cord blood HSCs/HPCs exhibit reduced expansion in the pres-
ence of SARS-CoV-2 S protein. (a-h) CD34+ enriched cells were plated
at 100,000–200,000 cells/mL in media with stimulating growth factors
and with PBS control, 1 μg/mL recombinant S protein alone, 1 μg/mL S
protein pre-incubated with 1 μg/mL SARS-CoV-2 neutralizing antibody
(Antibody), 1μg/mL S protein pre-incubated with 1μg/mL rhu ACE2, or
1 μg/mL S protein with 1 μg/mL Angiotensin1–7 (Ang1–7) and grown
for 7 days in 5%O2 and 5%CO2 at 37 °C. (a-d). Cells were then analyzed
by flow cytometry for the indicated cell populations and total cell
numbers were calculated or (e-h) 350–500 CD34+ cells were plated in
triplicate in 1% v/v methylcellulose with serum and growth factors and
grown for 12 days in 5% O2 and 5% CO2 at 37 °C. Total CFU were
calculated. n = 4/2 for (a-e)/(f-h), stats: generalized linear modelling
followed by ANOVA with TukeyHSD post hoc tests, matched colors
of points for 3a-e and matched symbols for points for 3f-h indicate the
same cord blood unit in different treatment conditions. For (f-h-
) significance codes shown are for the comparison of the indicated treat-
ment PBS control. *P < 0.05, **P < 0.005,***P < 0.0005
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expansion and numbers of HSCs/HPCs. We also examined
whether the S protein effects on expansion of HSCs/HPCs
and functional HPC CFU can be neutralized. Pre-incubation
of S protein with SARS-CoV-2 neutralizing antibody showed
a trend of rescuing expansion of several rigorously defined
hematopoietic populations, including total CD34+ cells,
HSCs, and CMPs/MEPs, and significantly enhanced expan-
sion of GMPs compared to S protein treatment alone (Fig.
S2a). The addition of Ang1–7 to the expansionmedia partially
rescued the expansion of CMP/MEP and significantly en-
hanced expansion of GMPs compared to S protein treatment
alone, with little effect on more primitive immunophenotypes
(Fig. S2b). Interestingly, both pre-incubation with the neutral-
izing antibody and the addition of Ang1–7 to the expansion
media showed a trend of rescuing the expansion of total cel-
lularity (Fig. 3f) and fully rescued the expansion of CFU-GM
(Fig. 3g) and CFU-GEMM (Fig. 3h). These data indicate that
the observed effects on expansion are due directly to exposure
to the recombinant S protein and provides insight into at least
partially neutralizing these effects.
Immune Cell Subpopulations Express Low Levels of
Cell Surface ACE2
To determine whether immune cells themselves are suscepti-
ble to infection, we isolated low density mononuclear cells
from PB of healthy donors. RNA was harvested from pooled
PB and subjected to RT-qPCR, revealing that ACE2 is
expressed at the mRNA level in these cells (Fig. 4a). Protein
was harvested from pooled PB and run on SDS-PAGE follow-
ed by immunoblotting with an antibody against ACE2 in non-
reducing conditions, revealing that ACE2 protein is detectable
in PB and that ACE2 runs at the predicted molecular weight of
the ACE2 homodimer as well as the ACE2 monomer; further,
there are two distinct bands visible on the western blot, pos-
sibly indicating that ACE2 is expressed as both its full-length
and cleaved isoforms in blood cells (Fig. 4b) [36]. We deter-
mined cell surface ACE2 expression on specific populations
of immune cells by flow cytometry analysis (Table S1, exam-
ple gating strategy Fig. S3). ACE2 is expressed on 1.4–3.7%
of low density PB cells, 0.9–2.6% of size-defined lympho-
cytes, 0.5–2.5% of size-defined low-density granulocytes,
and 0.3–0.9% of CD14+ monocytes. Examining more rigor-
ously defined subpopulations of immune cells, ACE2 is
expressed on 1.7–4% of CD19+ B-cells, 0.6–1.4% of CD3+
T-cells, 0.3–0.8% of CD3-CD56+ Natural Killer (NK) cells,
and 0.5–1.1% of CD3 + CD56+NKT-cells (Fig. 4c). Specific
subpopulations of T-cells also exhibit low numbers of ACE2+
cells, with ACE2 cell surface expression found on 0.3–0.7%
of CD4+ T-cells, 0.3–0.4% of CD8+ T-cells, 0.8–1.4% of
CD4-CD8- T-cells, and 2–8% of CD4 + CD8+ T-cells (Fig.
4c). PB CD34+ cells, which are enriched for HPC, have an
ACE2+ population of 0.7–1.4%, with one outlier sample
exhibiting cell surface ACE2 expression in over 30% of PB
derived CD34+ (Fig. 4c). This may be a technical artifact or
may be indicative of population variability of ACE2 expres-
sion on PB derived HPC. Together, these data indicate that
ACE2, which is thought to be the receptor protein primarily
responsible for SARS-CoV-2 infection, is expressed on the
cell surface of low numbers of PB immune cells.
Peripheral Blood Cells Respond to Exposure to the
SARS-CoV-2 S Protein
To examine effects of mature blood cell exposure to SARS-
CoV-2, low density PB cells were incubated with full length
recombinant SARS-CoV-2 S protein. Short-term 2 h incuba-
tion with S protein in the absence of serum leads to significant
increases in CD14 staining by flow cytometry (Fig. 5a, b) in
forward and side scatter defined monocytes. Additionally,
there is an accumulation of more CD14hi monocytes (Fig.
5c), with an average of 1.38-fold more per 1 × 105 total cells
relative to controls (Fig. 5d), though there are no significant
differences in number of total CD14+ monocytes (data not
shown). Thus, short-term exposure of PB to S protein induces
increased CD14 expression. We examined what effects S pro-
tein exposure has on PB cells when they are cultured longer in
the presence of serum. Overnight (18 h) incubation with S
protein leads to distinct changes in the morphology of PB cells
(Fig. 5e). Flow cytometry analysis of cells shows that cells in
in the monocyte size distribution become smaller (decrease in
forward scatter) and more granular (increase in side scatter)
compared to cells incubated with PBS (Fig. 5f). This shift in
morphology may be indicative of cell death, suggesting that
PBmonocytes grown ex vivo in the presence of S protein may
eventually undergo apoptosis or necrosis.
Discussion
Our results reveal previously unknown effects of SARS-CoV-
2 S protein exposure on HSCs, HPCs, and immune cells.
ACE2, the cell surface receptor protein to which SARS-
CoV-2 S protein binds and is currently considered the princi-
pal factor required for viral entry to host cells, is expressed at
low levels (<5%) on PB immune cells, including T-cells, B-
cells, NK cells, NKT cells, and monocytes. Despite this low
number of immune cells that are susceptible to ACE2 depen-
dent mechanisms of infection, ex vivo exposure to SARS-
CoV-2 S protein leads to distinct morphological changes in
PB monocytes. Most primitive and lineage committed HPC
derived from CB also include low numbers of ACE2+ cells
(<15%). Interestingly, HSCs consistently exhibit the highest
percentage of ACE2 expressing cells when compared to HPCs
and mature blood cells, though there is variability in ACE2
expressing populations from sample to sample. Importantly,
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ex vivo exposure of HSCs/HPCs to SARS-CoV-2 S protein
alters their functional proliferative/expansion characteristics.
Thus many hematologic manifestations of COVID-19 re-
ported may be due to direct SARS-CoV-2 impact on
HSCs/HPCs. Two common hematologic complications asso-
ciated with COVID-19 are thrombocytopenia and lymphope-
nia [4, 6, 17]. Interestingly, we observed significantly de-
creased capacity for the development of MLP when HSCs/
HPCs are treated ex vivo with SARS-CoV-2 S protein. MLP
are progenitors that differentiate into T-cells, B-cells and NK
cells, so dampening the ability of HSCs and MPPs to differ-
entiate to lymphoid primed cells may partly explain the lower
numbers of lymphocytes observed in COVID-19 patients.
Further, we also observed decreased numbers of CFU-GM
and CFU-GEMM when CD34+ cells are grown ex vivo in
the presence of S protein, as well as reduced expansion of
CMP/MEP/CFU-GEMM/CFU-GM when CD34+ cells are
expanded in the presence of S protein. Thus, it is possible that
the observed decreases in cells that are precursors to megakar-
yocytes may partially explain the reduction in circulating
platelets in COVID-19 patients. Given that HSCs exhibit a
higher subpopulation of ACE2+ cells than other primitive
and mature hematopoietic cells, it is also possible that these
observations are a result of SARS-CoV-2 impact on HSCs
themselves. Because of the large variability that we see in
ACE2 expressing HSC numbers, it is possible that the clinical
variability associated with SARS-CoV-2 may be in part ex-
plained by differing immune responses due to differential sus-
ceptibility of HSCs to SARS-CoV-2 infection/interactions.
Further, we observed that monocytes exhibit morphology
changes that may be indicative of cell death after incubation
with the S protein. This suggests that more mature immune
cells may be directly affected by SARS-CoV-2 exposure,
which could also explain the aforementioned hematologic
complications.
These data also provide interesting speculative insight
into mechanisms that may be at play in initiating a SARS-
CoV-2 induced cytokine storm syndrome (CSS). CSS is
an aberrant overactivation of cytokine signaling that leads
to a toxic excessive immune response [37–40]. There is
Fig. 4 Low numbers of
peripheral blood derived immune
cells express cell surface ACE2.
(a) RT-qPCR to test for ACE2
mRNA expression in low density
PB cells. ACE2 expression is
shown relative to GAPDH ex-
pression. (b) Protein was harvest-
ed from low density PB cells and
subjected to SDS-PAGE in non-
reducing conditions followed by
western blot with the indicated
antibodies (IB = immunoblot). (c)
Low density PB cells were
stained with fluorochrome conju-
gated antibodies and analyzed
with flow cytometry to define the
indicated immunophenotypes and
determine ACE2 expression on
these subpopulations. ACE2+
gate was defined using rabbit IgG
isotype control. Matched colors of
points indicate the same periph-
eral blood donor. ACE2 staining
n = 5, IgG control n = 5; stats: t-
tests comparing FITC+ % in
ACE2 staining versus IgG stain-
ing, corrected for multiple testing.
*P < 0.05
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evidence that monocytes play a key role in COVID-19
induced CSS [38, 41]. We demonstrated that ex vivo ex-
posure to SARS-CoV-2 S protein leads to an initial in-
crease in CD14hi monocytes. Interestingly, CD14hi cells
are increased in abundance and are associated with in-
creased production of inflammatory cytokines in
COVID-19 patients in the early recovery stage [40]. We
also observed that longer incubation ex vivo with S pro-
tein results in marked size reduction and increase in
granularity of the total monocyte population, which may
be indicative of monocyte cell death. There are two as-
pects of this study to note with respect to our findings.
First, we reported a very low number of immune cells
expressing the ACE2 receptor protein that is typically
associated with facilitating host cell interactions with
SARS-CoV-2. This includes monocytes, of which <1%
are ACE2+. This implies that a separate host cell receptor
may be interacting with SARS-CoV-2 S protein,
Fig. 5 Peripheral blood cells respond ex vivo to exposure to SARS-CoV-
2 S protein. (a-d) Low density PB was incubated for 2 h with 1 μg/mL
SARS-CoV-2 S recombinant S protein or PBS control. (a) Representative
histogram from 1 PB sample treated with S protein or PBS showing
CD14 expression of forward and side scatter gated monocytes and (b)
mean fluorescence intensities for CD14 staining. n = 4, stats: paired t-test,
different colors of points indicate PBs from the same donor. (c)
Representative contour plot from 1 PB sample treated with S protein or
PBS showing CD14 expression of forward and side scatter gated mono-
cytes, the gating strategy for CD14hi cells and (d) difference in CD14hi
monocytes represented as a fold-change of S protein treated cells relative
to PBS treated cells. n = 4, stats: paired t-test performed on total numbers
of CD14hi monocytes. (e-g) Low density PB was incubated for 18 h with
serum in the presence of 1 μg/mL SARS-CoV-2 S recombinant S protein
or PBS control. (e) Representative contour plot from 1 PB sample show-
ing all cells excluding debris and the monocyte gate used. (f) Mean values
for forward scatter (FSC) and (g) side scatter (SSC) of monocytes from
PB samples after incubation with S protein or PBS. n = 5, stats = paired t-
test, different colors of points indicate PBs from the same donor. FACS =
fluorescence activated flow cytometry. *P < 0.05, ***P < 0.0005
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underscoring the need to screen for additional host recep-
tors that may facilitate infection. Indeed, it has been pos-
tulated that this and other coronaviruses such as SARS-
CoV and MERS-CoV can infect host cells via S protein
binding to cell surface receptors that are not their “prima-
ry” receptor [42–46]. Second, in this study, PB cells and
HSCs/HPCs are only being exposed to SARS-CoV-2 pro-
tein, not the full viral particle, which indicates that SARS-
CoV-2 may impact cells regardless of whether viral entry
actually occurs in these cells. Perhaps SARS-CoV-2 S
protein induces or blocks signaling in these cells by bind-
ing ACE2 or other cell surface receptors. Thus, immune
cells may be directly affected by SARS-CoV-2 exposure
by interaction with viral proteins and not simply as a
result of normal host cell responses to infection.
Understanding intracellular effects of SARS-CoV-2 S
protein on HSCs/HPCs is a next step in experimental
evaluation.
TMPRSS2 is a cell surface protease that has demonstrated
catalytic activity against SARS-CoV-2 S protein and ACE2
[13, 36] and may play a role in SARS-CoV-2 infection [13].
During the course of these studies, we also explored
TMPRSS2 expression in low density PB and CB CD34+
enriched cells, but we did not detect its expression by RT-
qPCR or western blot (data not shown). This may indicate it
is not expressed in these cells or it is just expressed on a low
percentage of a specific subpopulation of cells and is therefore
below our limit of detection. Early studies focusing on SARS-
CoV-2 indicated proximal cell surface TMPRSS2 protein is
required to cleave S protein into two subunits, S1 and S2,
priming the virus for host entry [13]. However, a recent study
demonstrated that virus pseudotyped using SARS-CoV-2 S
protein can infect cells expressing ACE2 regardless of
TMPRSS2 expression, and that infection is not enhanced by
expression of TMPRSS2 [47]. Thus, the occurrence of
TMPRSS2 expression may not immediately rule out that a
specific type of cell can be impacted by interaction with the
virus. This is important to consider while evaluating host tis-
sues for susceptibility to viral infection and warrants further
studies.
Importantly, we also examined several methods which are
proposed to inhibit SARS-CoV-2 infection in the context of
neutralizing S protein impacts on HSCs/HPCs. We observed
that many of the effects induced by the S protein on hemato-
poietic cells ex vivo can be neutralized by antibodies targeting
the S protein, by treatment with soluble recombinant human
ACE2, or by treatment with Angiotensin1–7. Current and past
studies have proposed and demonstrated the feasibility of
using similar therapeutic interventions for the treatment of
SARS-CoV-2 infection [26, 33, 34, 48]. Future studies should
explore whether these agents may be used therapeutically to
specifically target the effects on the hematopoietic system
induced by SARS-CoV-2 exposure, (i.e. to prevent or reverse
thrombocytopenia or lymphopenia in COVID-19 patients).
A limitation of our studies is that we performed our func-
tional assays using recombinant S protein instead of live virus.
It will be important to determine answers to several outstand-
ing questions to fully understand the impact of SARS-CoV-2
and potentially other coronaviruses on the hematopoietic and
immune systems so that wemay better understand how to treat
this particular facet of the disease: 1) Are HSCs/HPCs and
immune cells directly impacted by exposure to live SARS-
CoV-2? 2) Are HSCs/HPCs and immune cells simply impact-
ed by exposure to SARS-CoV-2, perhaps by an aberrant in-
duction of signaling pathways, or are these cells actually in-
fected? If they are infected, what form does the infection take
(i.e., is it an abortive infection that does not lead to active
replication of the virus, thus accounting for the low viral titer
found in blood samples?) 3) How long does the virus remain
in or interactive with cells? Can HSCs/HPCs and immune
cells actually act as harbor for dormant SARS-CoV-2 parti-
cles, allowing for a re-emergence of symptoms after the pa-
tient initially recovers? 4) Can hematologic manifestations of
COVID-19 be treated by directly targeting the mechanisms by
which HSCs/HPCs are impacted by SARS-CoV-2, and 5)
what are the implications for HCT by bone marrow, CB, or
mobilized PB that may have been exposed to SARS-CoV-2?
While the world awaits much-anticipated vaccines to
SARS-CoV-2, it is critical for the scientific community to
fully assess all host tissues that may be impacted by infection
and to explore short- and long-term implications for infections
in the context of these tissues. We have demonstrated that
specific subpopulations of HSCs/HPCs and immune cells ex-
press ACE2 receptor, which may make them vulnerable to
infection/interaction with SARS-CoV-2. Importantly, our data
along with the recent report by Ratacjzak, et al. [26] suggests
that HSCs may be particularly susceptible, and this vulnera-
bility may vary greatly from patient to patient, which may
partly explain variability in patient responses that has been
reported. We have also shown that exposure to just one small
piece of the SARS-CoV-2 viral particle, S protein, can induce
both phenotypic and functional changes in HSCs/HPCs as
well as aberrant changes in morphology in PB monocytes,
suggesting that even absent a true infection of these cells,
SARS-CoV-2 may impact the functional ability of these cells,
thus affecting the host response to infection.
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